 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug METOPROLOL TARTRATE: The risk of angioedema is not mentioned in the METOPROLOL TARTRATE label, indicating that there is no known increase or decrease in risk associated with [0m
[34mMETOPROLOL TARTRATE according to the FDA label information.[0m
[1;34m2[0m[34m. Drug LABETALOL: Labetalol can increase the risk of angioedema, but this is considered a rare adverse reaction.[0m
[1;34m3[0m[34m. Drug ATENOLOL: The final answer to the question [0m[34m"Does ATENOLOL increase or decrease the risk of angioedema?"[0m[34m is that according to the FDA label data provided by FDAHandler, ATENOLOL does not [0m
[34mincrease the risk of angioedema. Angioedema is not listed as a side effect in the adverse reactions section of the ATENOLOL label. However, it is important to note that other medications in the same [0m
[34mclass as atenolol, such as ACE inhibitors, have been associated with angioedema. Additionally, patients taking beta blockers with a history of anaphylactic reactions may have a more severe reaction [0m
[34mand may be unresponsive to usual treatments for allergic reactions.[0m
[34m                ---------[0m
[34m                Does the beta blocker category of drugs increase the risk of[0m
[34m                angioedema, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-angioedema-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"According to the provided passages:"[0m[32m,[0m
[32m      [0m[32m"- METOPROLOL TARTRATE does not have a known increase or decrease in the risk of angioedema as per its FDA label."[0m[32m,[0m
[32m      [0m[32m"- LABETALOL can increase the risk of angioedema, but this is considered a rare adverse reaction."[0m[32m,[0m
[32m      [0m[32m"- ATENOLOL does not increase the risk of angioedema according to its FDA label, and angioedema is not listed as a side effect."[0m[32m,[0m
[32m      [0m[32m"Given that two of the drugs [0m[32m([0m[32mMETOPROLOL TARTRATE and ATENOLOL[0m[32m)[0m[32m show no clear effect on the risk of angioedema and one drug [0m[32m([0m[32mLABETALOL[0m[32m)[0m[32m shows a rare increase in risk, the overall effect of the [0m
[32mbeta blocker category on the risk of angioedema is not consistent across all drugs."[0m[32m,[0m
[32m      [0m[32m"The evidence suggests that while there may be a rare increase in risk with some beta blockers like LABETALOL, this is not a common effect for the category as a whole."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the beta blocker category of drugs on the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"According to the provided passages:"[0m[34m,[0m
[34m      [0m[34m"- METOPROLOL TARTRATE does not have a known increase or decrease in the risk of angioedema as per its FDA label."[0m[34m,[0m
[34m      [0m[34m"- LABETALOL can increase the risk of angioedema, but this is considered a rare adverse reaction."[0m[34m,[0m
[34m      [0m[34m"- ATENOLOL does not increase the risk of angioedema according to its FDA label, and angioedema is not listed as a side effect."[0m[34m,[0m
[34m      [0m[34m"Given that two of the drugs [0m[34m([0m[34mMETOPROLOL TARTRATE and ATENOLOL[0m[34m)[0m[34m show no clear effect on the risk of angioedema and one drug [0m[34m([0m[34mLABETALOL[0m[34m)[0m[34m shows a rare increase in risk, the overall effect of the [0m
[34mbeta blocker category on the risk of angioedema is not consistent across all drugs."[0m[34m,[0m
[34m      [0m[34m"The evidence suggests that while there may be a rare increase in risk with some beta blockers like LABETALOL, this is not a common effect for the category as a whole."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the beta blocker category of drugs on the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. According to the provided passages:[0m
[1;31m2[0m[31m. - METOPROLOL TARTRATE does not have a known increase or decrease in the risk of angioedema as per its FDA label.[0m
[1;31m3[0m[31m. - LABETALOL can increase the risk of angioedema, but this is considered a rare adverse reaction.[0m
[1;31m4[0m[31m. - ATENOLOL does not increase the risk of angioedema according to its FDA label, and angioedema is not listed as a side effect.[0m
[1;31m5[0m[31m. Given that two of the drugs [0m[1;31m([0m[31mMETOPROLOL TARTRATE and ATENOLOL[0m[1;31m)[0m[31m show no clear effect on the risk of angioedema and one drug [0m[1;31m([0m[31mLABETALOL[0m[1;31m)[0m[31m shows a rare increase in risk, the overall effect of the beta [0m
[31mblocker category on the risk of angioedema is not consistent across all drugs.[0m
[1;31m6[0m[31m. The evidence suggests that while there may be a rare increase in risk with some beta blockers like LABETALOL, this is not a common effect for the category as a whole.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the beta blocker category of drugs on the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally correct. The conclusion that there is no clear effect of the beta blocker category of drugs on the risk of angioedema is supported by the evidence [0m
[32mpresented: one drug in the category has a rare increase in risk, while the others show no clear effect. The reasoning correctly synthesizes the information from the individual drugs to make a [0m
[32mconclusion about the category as a whole. No flaws are identified in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally correct. The conclusion that there is no clear effect of the beta blocker category of drugs on the risk of angioedema is supported by the evidence [0m
[34mpresented: one drug in the category has a rare increase in risk, while the others show no clear effect. The reasoning correctly synthesizes the information from the individual drugs to make a [0m
[34mconclusion about the category as a whole. No flaws are identified in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally correct. The conclusion that there is no clear effect of the beta blocker category of drugs on the risk of angioedema is supported by the evidence[0m
[31mpresented: one drug in the category has a rare increase in risk, while the others show no clear effect. The reasoning correctly synthesizes the information from the individual drugs to make a [0m
[31mconclusion about the category as a whole. No flaws are identified in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.8[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.1[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"rare"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The beta blocker category of drugs does not show a consistent effect on the risk of angioedema across different drugs. METOPROLOL TARTRATE and ATENOLOL show no known effect, [0m
[32mwhile LABETALOL has a rare increase in risk. The evidence is weak because it is based on the absence of information in the FDA label for two drugs and a rare adverse reaction for one drug."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
